A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.
Arce C, Pérez-Plasencia C, González-Fierro A, de la Cruz-Hernández E, Revilla-Vázquez A, Chávez-Blanco A, Trejo-Becerril C, Pérez-Cárdenas E, Taja-Chayeb L, Bargallo E, Villarreal P, Ramírez T, Vela T, Candelaria M, Camargo MF, Robles E, Dueñas-González A.
Arce C, et al.
PLoS One. 2006 Dec 20;1(1):e98. doi: 10.1371/journal.pone.0000098.
PLoS One. 2006.
PMID: 17183730
Free PMC article.
Clinical Trial.